SEC Filings

Filing links are provided when reliable SEC filing data is available.

Recent Filings

Form	Filing Date	Accepted	Document
4	Aug 25, 2026	Aug 25, 2026	View filing
4	Aug 25, 2026	Aug 25, 2026	View filing
4	Aug 19, 2026	Aug 19, 2026	View filing
4	Aug 10, 2026	Aug 10, 2026	View filing
4	Aug 5, 2026	Aug 5, 2026	View filing
4	Aug 5, 2026	Aug 5, 2026	View filing
F-6 POS	Jul 29, 2026	Jul 29, 2026	View filing
10-Q	Jul 29, 2026	Jul 29, 2026	View filing
8-K	Jul 29, 2026	Jul 29, 2026	View filing
4	Jun 22, 2026	Jun 22, 2026	View filing
4	Jun 16, 2026	Jun 16, 2026	View filing
4	Jun 8, 2026	Jun 8, 2026	View filing
4	Jun 8, 2026	Jun 8, 2026	View filing
4	Jun 8, 2026	Jun 8, 2026	View filing
4	Jun 8, 2026	Jun 8, 2026	View filing
4	Jun 8, 2026	Jun 8, 2026	View filing
4	Jun 8, 2026	Jun 8, 2026	View filing
4	Jun 8, 2026	Jun 8, 2026	View filing
4	Jun 8, 2026	Jun 8, 2026	View filing
4	Jun 8, 2026	Jun 8, 2026	View filing
4	Jun 8, 2026	Jun 8, 2026	View filing
4	Jun 4, 2026	Jun 4, 2026	View filing
4	Jun 1, 2026	Jun 1, 2026	View filing
4	Jun 1, 2026	Jun 1, 2026	View filing
4	Jun 1, 2026	Jun 1, 2026	View filing
4	Jun 1, 2026	Jun 1, 2026	View filing
4	Jun 1, 2026	Jun 1, 2026	View filing
4	Jun 1, 2026	Jun 1, 2026	View filing
4	Jun 1, 2026	Jun 1, 2026	View filing
4	Jun 1, 2026	Jun 1, 2026	View filing

About Teva Pharmaceutical Industries Limited

Teva Pharmaceutical Industries Limited functions as a global pharmaceutical enterprise, involved in the conception, manufacturing, marketing, and provision of a broad spectrum of generic, specialty, and biopharmaceutical products throughout North America, Europe, and various international markets. The company's diverse product range includes sterile items, hormones, potent drugs, and cytotoxic agents, available in numerous forms like tablets, capsules, injectable solutions, inhalable preparations, liquids, transdermal patches, topical ointments, and creams. Additionally, Teva develops, produces, and sells active pharmaceutical ingredients (APIs). The firm prioritizes several key therapeutic domains: central nervous system disorders, pain management, respiratory ailments, and oncology. In the central nervous system sector, prominent products include Copaxone, intended for relapsing forms of multiple sclerosis; AJOVY, prescribed for preventing migraines; and AUSTEDO, which targets tardive dyskinesia and chorea linked to Huntington's disease. For respiratory conditions, Teva offers medications such as ProAir, QVAR, ProAir Digihaler, AirDuo Digihaler, ArmonAir Digihaler, BRALTUS, CINQAIR/CINQAERO, DuoResp Spiromax, and AirDuo RespiClick/ArmonAir RespiClick, all designed to treat asthma and chronic obstructive pulmonary disease. The oncology portfolio features therapies like Bendeka, Treanda, Granix, Trisenox, Lonquex, and Tevagrastim/Ratiograstim. Teva Pharmaceutical Industries Limited is also engaged in a collaboration with MedinCell to advance and commercialize multiple long-acting injectable formulations, notably a risperidone suspension for individuals affected by schizophrenia. The company was established in 1901 and its primary headquarters are located in Tel Aviv-Yafo, Israel.

Tel Aviv, TA

32,008 employees

www.tevapharm.com

Healthcare / Drug Manufacturers - Specialty & Generic

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
CEO: Richard D. Francis

View full financials